Biomaterials for cancer immunotherapy

Immunotherapy has emerged as a potent strategy for addressing numerous cancers, marked by a growing array of approved therapeutics and a substantial pipeline of innovative candidates undergoing clinical and preclinical evaluations. Nevertheless, the current landscape of cancer immunotherapy encounters various challenges within clinical settings, such as resistance, recurrence, toxicity, and adverse side effects. The Gong Lab is dedicated to devising advanced drug delivery systems and biomaterials aimed at optimizing the impact of immunotherapy, enhancing its efficacy, and mitigating the risks of toxicity and side effects. Specific areas of research interest encompass the formulation of gene delivery strategies to prevent cancer recurrence, the engineering of antibodies to ensure safer cancer immunotherapy, and the manipulation of immune cells to address issues related to resistance.